C4 Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

c4therapeutics.com

Executives

10

C4 Therapeutics Management Team

10 Team Members

C4 Therapeutics has 10 executives. C4 Therapeutics's founder is Marc A. Cohen. C4 Therapeutics's current Chief Executive Officer, President is Andrew J Hirsch.

Name

Work History

Title

Status

Marc A. Cohen

Founder

Current

Andrew J Hirsch

Chief Executive Officer, President

Current

Stewart L. Fisher Ph.D.

President, Senior Vice President

Current

Roy Pollock

President, Senior Vice President

Current

Ruth Turner

President, Senior Vice President

Current

Name

Marc A. Cohen

Andrew J Hirsch

Stewart L. Fisher Ph.D.

Roy Pollock

Ruth Turner

Work History

Title

Founder

Chief Executive Officer, President

President, Senior Vice President

President, Senior Vice President

President, Senior Vice President

Status

Current

Current

Current

Current

Current

You May Also Like

Amphista Therapeutics Logo
Amphista Therapeutics

Amphista Therapeutics is a biopharmaceutical company that creates cancer therapeutics that harness the body's natural processes to selectively and efficiently degrade and remove disease-causing proteins.

P
Pin Therapeutics

Pin Therapeutics is a pharmaceutical company that creates therapeutic products based on chemical biology-driven protein degradation, including PROTAC technology. The company aims to develop PROTAC compounds for oncology, neurodegenerative diseases, and cardiovascular indications based on disease-agnostic approaches.

F
FIMECS

FIMECS is a drug discovery biotech firm focused on developing protein degradation therapeutics for cancers and other difficult-to-treat diseases.

Arvinas Logo
Arvinas

Arvinas (NASDAQ: ARVN) is a pharmaceutical company focused on developing small molecules aimed at degrading disease-causing cellular proteins. The company is translating these protein degradation approaches into drugs for the treatment of cancer and other diseases. Many diseases are a result of "rogue," uncontrolled proteins, whose absence could bring great clinical benefit to patients.

Kymera Therapeutics Logo
Kymera Therapeutics

Kymera Therapeutics (NASDAQ: KYMR) is a biotechnology company that develops an approach to treating previously untreatable diseases. Kymera aims to accelerate drug discovery with an ability to target and degrade proteins and advance treatment options for patients.

Nurix Therapeutics Logo
Nurix Therapeutics

Nurix Therapeutics discovers drugs that harness the body's natural process to control protein levels. The drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.